Paraneoplastic neurological syndromes a review

Neurologist

Volumn 15, Issue 1, 2009, Pages 21-33

  Toothaker, Thomas B ^a,b   Rubin, Michael ^a  

^a Department of Obstetrics Gynecology   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Diagnosis; Paraneoplastic disorders; Pathophysiology; Treatment

Indexed keywords

(3 IODOBENZYL)GUANIDINE; AZATHIOPRINE; BACLOFEN; BENZODIAZEPINE; CANCER ANTIBODY; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CORTICOTROPIN; CYCLOSPORIN; DIAMINOPYRIDINE; DIAZEPAM; FLUORODEOXYGLUCOSE F 18; HU ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PLACEBO; PYRIDINE DERIVATIVE; RITUXIMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

BREAST CANCER; CELLULAR IMMUNITY; CEREBELLUM DEGENERATION; CLINICAL FEATURE; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; HUMAN; IMMUNE RESPONSE; LUNG SMALL CELL CANCER; MOTOR NEURON DISEASE; MYASTHENIA GRAVIS; MYOKYMIA; MYOSITIS; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSOCLONUS MYOCLONUS SYNDROME; OVARY CANCER; PARANEOPLASTIC NEUROPATHY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SENSORY NEUROPATHY; STIFF MAN SYNDROME; THYMECTOMY; THYMOMA; TREATMENT RESPONSE; TUMOR GROWTH; WHOLE BODY SCINTISCANNING;

AUTOANTIBODIES; HUMANS; ISAACS SYNDROME; MYASTHENIA GRAVIS; MYOSITIS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; RETINAL DISEASES; STIFF-PERSON SYNDROME;

EID: 59549106384     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181870aa2     Document Type: Review

References (150)

1. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Eng J Med. 2003;349:1543-1554.
2. Darnell RB. Onconeural antigens and paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acd Sci USA. 1996;93:4529-4536.
3. Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulin, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:479-482.
4. Cooper R, Khakoo Y, Matthey KK, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol. 2001;36:623-629.
5. Rosenblum MK. Paraneoplasia and autoimmunologic injury of the nervous system: the anti-Hu syndrome. Brain Pathol. 1993;3:199-212.
6. Lawn ND, Westmoreland BF, Kiely MJ, et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003;78:1363-1368.
7. Darnell RB. Paraneoplastic neurologic disorders. Arch Neurol. 2004;61:30-32.
8. Musunuru K, Darnell RB. Paraneoplastic neurologic disease antigens. Annu Rev Neurosci. 2001;24:239-262.
9. Darnell RB, Furneaux HM, Posner JB. Antiserum from a patient with cerebellar degeneration identifies a novel protein in Purkinje cells, cortical neurons and neuroectodermal tumors. J Neurosci. 1991;11:1224-1230.
10. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56:715-719.
11. Drlicek M, Bianchi G, Bogliun G, et al. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol. 1997;244:85-89.
12. Graus F, Dalmau J, Reñé M, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997;15:2866-2872.
13. Sculier JP, Feld R, Evans WK, et al. Neurologic disorders in patients with small cell lung cancer. Cancer. 1987;60:2275-2283.
14. Suete T, Leffers P, Ten Velde GP, et al. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer. 2004; 100:801-806.
15. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res. 2004;10:7270-7275.
16. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol. 1995;37(suppll):S32-S42.
17. Bataller L, Dalmau J. Paraneoplastic neurologic syndromes: approaches to diagnosis and treatment. Sem in Neurol. 2003;23:215-224.
18. Greenlee JE. Recommended diagnostic criteria for paraneoplastic neurological syndromes: editorial commentary. J Neurol Neurosurg Psychiatry. 2004;75:1090.
19. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135-1140.
20. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J of Rare Dis. 2007;2:22.
21. Linke R, Schroeder M, Helmberger T, et al. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63:282-286.
22. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127:2331-2338.
23. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. European J Neurol. 2006;13:682-690.
24. Rutherford GC, Dineen RA, O'Connor A. Imaging in the investigation of paraneoplastic syndromes. Clinical Radiology. 2007;62:1021-1035.
25. Graus F, Florence KG, Reñé R, et al. Anti-Hu associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138-1148.
26. Dalmau J, Graus F, Rosenblum MK, et al. Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuropathy: a clinical study of 71 patients. Medicine. 1992;71:59-72.
27. Byrne T, Mason WP, Posner JB, et al. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry. 1997;62:276-278.
28. Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol. 1999;9:275-284.
29. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 2006;33:270-298.
30. Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet. 1993;341:21-22.
31. Roberts WK, Darnell RB. Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immonol. 2004;16:616-622.
32. Dalmau J, Furneaux HM, Gralla RJ, et al. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer: a quantitative western blot analysis. Ann Neurol. 1990;27:544-552.
33. Furneaux HM, Reich L, Posner JB. Auto-antibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology. 1990;40:1085-1091.
34. Kim YI. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve. 1986;9:523-530.
35. Toyka KV, Drachman DB, Pestronk A, et al. Myasthenia gravis, passive transfer from man to mouse. Science. 1975;190:397-399.
36. Graus F, Illa I, Agusti M, et al. Effect of intraventricular injection of anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci. 1991;106:82-87.
37. Sillevis Smitt PAE, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology. 1995;45:1873-1878.
38. Tanaka K, Ding X, Tanaka M. Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary cultured neurons. J Neurol Sci. 2004;217:25-30.
39. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47:9-17.
40. Corsellis JA, Goldberg GJ, Norton AR. Limbic encephalitis and its association with carcinoma. Brain. 1968;91:481-496.
41. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain. 2000;123:1481-1494.
42. Dalmau J, Tuziin E, Wu H, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61:25-36.
43. Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999;340:1788-1795.
44. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2 associated encephalitis. Brain. 2004;127:1831-1844.
45. Tüzün E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis, and treatment. The Neurologist. 2007;13:261-271.
46. Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764-1777.
47. Whitley RJ. Herpes simplex encephalitis. Antiviral Res. 2006;71:141-148.
48. Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies. The Neurologist. 2007;13:140-147.
49. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127:701-712.
50. Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004;62:1177-1182.
51. Brouwer B. Les affections parenchymateuse du cervelet et leur signification du point de vue de l'anatomie et de la physiologie de cet organe. J Beige Neurol Pscychiat. 1938;38:691-677.
52. Peterson K, Rosenblum MK, Kotanides H, et al. Paraneoplastic cerebellar degeneration I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurol. 1992;42:1931-1937.
53. Hammack J, Kotanides H, Rosenblum MK, et al. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurol. 1992;42:1938-1943.
54. Shams'ili S, Grefkens J, de Leewu B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409-1418.
55. Widdess-Walsh P, Tavee JO, Schuele S, et al. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol. 2003;63:187-190.
56. Phuphanich S, Brock C. Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol. 2007;81:67-69.
57. Clouston PD, Saper CB, Arbizu T, et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurol. 1992;42:1944-1950.
58. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 1997;120:1279-1300.
59. Wong A. An update on opsoclonus. Curr Opin Neurol. 2007;20:24-31.
60. Tate ED, Allison TJ, Pranzatelli MR, et al. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs. 2005;22:8-19.
61. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineural antibodies-a report from the Children's Cancer Group study. Med Pediatr Oncol. 2001;36:612-622.
62. Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology. 2004;62:1526-1532.
63. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2006;28:585-593.
64. Blaes F, Fühlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol. 2005;58:313-317.
65. Korfei M, Fühlhuber V, Schmidt-Wöll T, et-al. Functional characterization of autoantibodies from patients with pediatric opsoclonus-myoclonus syndrome. J Neuroimmol. 2005;170:150-157.
66. Airman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myolconus and neuroblastoma. Cancer. 1976;37:846-852.
67. Luque F, Furneaux H, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29:241-251.
68. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53:580-587.
69. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124:437-443.
70. Lockman J, Burns TM. Stiff-person syndrome. Pract Neurol. 2007;7:106-108.
71. Murinson BB. Stiff-person syndrome. Neurologist. 2004;10:131-137.
72. Meinck HM, Ricker K, Hulser PJ, et al. Stiff-man syndrome: neurophysiological findings in eight patients. J Neurol. 1995;242:134-142.
73. Lorish TR, Thorsteinsson G, Howard FM. Stiff-man syndrome up-dated. Mayo Clin Proc. 1989;64:629-636.
74. Solimena M, Folli F, Denis-Donini S, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. 1988;318:1012-1020.
75. McCabe DJH, Turner NC, Chao D, et al. Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. Neurology. 2004;62:1402-1404.
76. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in stiff-man syndrome. Neuron. 2000;26:307-312.
77. Schiff D, Dalmau J, Myers DJ. Anti-GAD antibody positive stiff-limb syndrome in multiple myeloma. J neurooncol. 2003;65:173-175.
78. Sommer C, Weishaupt A, Brinkhoff J, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005;365:1406-1411.
79. Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol. 2005;252(suppl 1): 19-25.
80. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immunoglobulin for stiff-person syndrome. N Engl J Med. 2001;345:1870-1876.
81. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58:96-107.
82. Damek DM. Paraneoplastic retinopathy/optic neuropathy. Curr Treat Options Neurol. 2005;7:57-67.
83. Bataller L, Dalmau J. Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol. 2004;17:3-8.
84. Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal call apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol. 2002;132:72-82.
85. Ohguro H, Maruyama I, Nakazawa M, et al. Antirecoverin antibody in the aqueous humor of patients with cancer-associated retinopathy. Am J Ophthalmol. 2002;134:605-607.
86. Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol. 2004;4:5-13.
87. Kikuchi T, Arai J, Shibuki H, et al. Tubby-like protein 1 as an autoantigen in cancer-associated retinopathy. J Neuroimmunol. 2000;103:26-33.
88. Eichen J, Dalmau J, Demopoulos A, et al. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol. 2001;21:168-172.
89. Tateiwa H, Gotoh N, Ichikawa M, et al. Molecular cloning and characterization of human PTB-like protein: a possible retinal autoantigen of cancer-associated retinopathy. J Neuroimmunol. 2001;120:161-169.
90. Jacobson DM, Adamus G. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon cancer. Am J Ophthalmol. 2001;131:806-808.
91. Pföhler C, Preuss KD, Tilgen W, et al. Mitofilin and titin as target antigens in melanoma-associated retinopathy. Int J Cancer. 2006;120:788-795.
92. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic optic neuritis with retinitis denned by CRMP-5-IgG. Ann Neurol. 2003;54:38-50.
93. Rowland LP, Shceider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688-1700.
94. Chiò A, Brignolio F, Meineri P, et al. Motor neuron disease and malignancies: results of a population-based study. J Neurol. 1988;235:374-375.
95. Kurtzke JF, Beebe GW. Epidemiology of amyotrophic lateral sclerosis: 1. a case control comparison based on ALS deaths. Neurology. 1980;30:453-462.
96. Stich O, Kleer B, Rauer S. Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease. J Neurol Neurosurg Psychiatry. 2007;78:883-885.
97. Khwaja S, Sripathi N, Ahmad BK, et al. Paraneoplastic motor neuron disease with type 1 purkinje cell antibodies. Muscle Nerve. 1998;21:943-945.
98. Verma A, Berger JR, Snodgrass S, et al. Motor neuron disease: a paraneoplastic process associated with anti-Hu antibody and small-cell lung carcinoma. Ann Neurol. 1996;40:112-116.
99. Forsyth PA, Dalmau J, Graus F, et al. Motor neuron syndromes in cancer patients. Ann Neurol. 1997;41:722-730.
100. Rowland LP, Sherman WH, Latov N, et al. Amyotrophic lateral sclerosis and lymphoma: bone marrow examination and other diagnostic tests. Neurology. 1992;42:1101-1102.
101. Gordon PH, Rowland LP, Younger DS, et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology. 1997;48:1671-1678.
102. Antoine JC, Camdessanche JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol. 2007;6:75-86.
103. Molinuevo JL, Graus F, Serrano C, et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol. 1998;44:976-980.
104. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol. 2005;18:598-603.
105. Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiologic study of 20 patients. Brain. 2002;124:1138-1148.
106. Oh SJ, Gurtekin Y, Dropcho EJ, et al. Anti-Hu antibody neuropathy: a clinical, eletrophysiologic, and pathologic study. Clin Neurophysiol. 2005;116:28-34.
107. Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiologic basis of sensory neuronopathies (ganglionopathies). Muscle Nerve. 2004;30:255-268.
108. Antoine JC, Honnoret J, Camdessanche JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49:214-221.
109. Eurelings M, Lokhurst HM, Kalmijn S, et al. Malignant transformation in polyneuropathy associated with monoclonal gammopafhy. Neurology. 2005;64:2079-2084.
110. Levine T, Pestronk A, Floence J, et al. Peripheral neuropathies in Waldenstrom's macroglobulinemia. J Neurol Neurosurg Psychiatry. 2006;77:224-228.
111. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496-2506.
112. Maddison P. Neuromyotonia. Clin Neurophysiol. 2006;117:2118-2127.
113. Löscher WN, Wanschitz J, Reiners K, et al. Morvan's syndrome: clinical, laboratory, and in vitro electrophysiological studies. Muscle Nerve. 2004; 30:157-163.
114. AAEM Quality Assurance Committee. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001;24:1236-1238.
115. Gutmann L, Gutmann L. Myokymia and neuromyotonia 2004. J Neurol. 2004;251:138-142.
116. Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol. 1995;38:714-722.
117. Mygland A, Vincent A, Newsome-Davis J, et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol. 2000;57:527-531.
118. Lahrmann H, Albrecht G, Drlicek M, et al. Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle Nerve. 2001;24:834-838.
119. Direkze NC, Stevenson VL, Schwartz MS, et al. Wriggling muscles as a sign of lung carcinoma. JR Soc Med. 2000;93:373-374.
120. Toepfer M, Schroeder M, Unger JW, et al. Neuromyotonia, myoclonus, sensory neuropathy and cerebellar symptoms in a patient with antibodies to neuronal nucleoproteins (anti-Hu-antibodies). Clin Neurol Neurosurg. 1999; 101:207-209.
121. van den Berg JS, van Engelen BG, Boerman RH, et al. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol. 1999;246:623-625.
122. Mareska M, Gutmann L. Lambert-Eaton myasthenic syndrome. Semin Neurol. 2004;24:149-153.
123. Sanders DB. Lambert-Eaton myasthenic syndrome, diagnosis and treatment. Ann NY Acad Sci. 2003;998:500-508.
124. Wirtz PW, Sotodeh M, Nijnuis M, et al. Differences in distribution of muscle weakness between myasthenia gravis and the Lambert Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2002;73:766-768.
125. Wirtz PW, Smallegange TM, Wintzen AR, et al. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002; 104:359-363.
126. Lennon VA. Serological profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology. 1997;48:S23-S27.
127. Sutton I, Winer J. The immunopathogenesis of paraneoplastic neurological syndromes. Clin Sci. 2002;102:475-486.
128. Chalk CH, Murray N, Newsome-Davis J, et al. Response of Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990;40:1552-1556.
129. Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000; 54:603-607.
130. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004;29:484-505.
131. Marx A, Müller-Hermellink HK, Ströbel P. The role of thymomas in the development of myasthenia gravis. Ann NY Acad Sci. 2003;998:223-236.
132. Scherer K, Bedlack RS, Simel DL. Does this patient have myasthenia gravis? JAMA. 2005;293:1906-1914.
133. AAEM Quality Assurance Committee. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2001;24:1239-1247.
134. Conti-Fine BM, Malani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116:2843-2854.
135. Evoli A, Minicuci GM, Vitaliani R, et al. Paraneoplastic diseases associated with thymoma. J Neurol. 2007;254:756-762.
136. Evoli A. Clinical aspects of neuromuscular transmission disorders. Acta Neurol Scand Suppl. 2006;183:8-11.
137. Hoch W, McConville J, Helms S, et al. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365-368.
138. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;24:49-62.
139. Kim HK, Park MS, Choi YS, et al. Neurologic outcomes of thymectomy in myasthenia gravis: comparative analysis of the effect of thymoma. J Thorac Cardiovasc Surg. 2007;134:601-607.
140. Alexanderson H, Lundberg IE.. Inflammatory muscle disease: clinical presentation and assessment of patients. Curr Rheumatol Reports. 2007;9:273-279.
141. Dalakas MC. Advances in the immunobiology and treatment of inflammatory myopathies. Curr Rheumatol Reports. 2007;9:291-297.
142. Briani C, Doria A, Sarzi-Puttini P, et al. Update on idiopathic inflammatory myopathies. Autoimmunity. 2006;39:161-170.
143. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007;6:620-631.
144. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96-100.
145. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy, a population based cohort study. Ann Intern Med. 2001;134:1087-1095.
146. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85:41-45.
147. Amoura Z, Duhaut P, Huong du LT, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev. 2005;14:1279-1282.
148. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682-3689.
149. Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist. 2006;11:292-305.
150. Lorusso L, Hart IK, Ferrari D, et al. Autonomic paraneoplastic neurological syndromes. Autoimmun Rev. 2007;6:162-168.